跳至主要内容
临床试验/CTRI/2011/091/000140
CTRI/2011/091/000140已完成3 期

A randomized, open label, comparative, multicentric, phase 3 clinical study to assess the efficacy and safety of Blonanserin tablets in comparison with Haloperidol tablets in patients suffering from schizophrenia - None

Cadila Healthcare Ltd0 个研究点目标入组 200 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients between 18-65 years of age.
  • 2.Patients with diagnosis of schizophrenia.
  • 3.Informed consent.

排除标准

  • 1.Pregnancy and/or lactation.
  • 2.Patients with suicidal tendencies.
  • 3.Patients with relevant CNS disorders or history of such disorders.
  • 4.Patients with a history of neuroleptic malignant syndrome (NMS).
  • 5.Patients with uncontrolled diabetes or significant cardiovascular diseases.
  • 6.Patients with angle-closure glaucoma, benign prostatic hyperplasia, urinary retention or paralytic ileus.
  • 7.Patients with significant renal or hepatic impairment, acute infections, leucopenia, hyperthyroidism or SIADH.
  • 8.Impoverished patients.
  • 9.Patients with an organic psychiatric disorder.
  • 10.History of hypersensitivity to study medication.
  • 11.Patients requiring concomitant treatment which is not permissible.
  • 12.Patients with any other serious concurrent illness or malignancy.
  • 13.Patients with continuing history of alcohol and/or drug abuse.
  • 14.Participation in another clinical trial in the past 3 months.

研究者

相似试验